Tocenar 50 mg Powder for concentrate for solution for infusion
PDF Leaflet Revision Date: 25 April 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with newly diagnosed acute myeloid leukaemia.
Dosage (summary)
20 mg/mu00b2 IV infusion daily for 5 days, repeated every 4 weeks.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; potential risk to fetus.
Key Drug Interactions
- Caution with drugs activated by phosphorylation
- Caution with cytidine deaminase inhibitors
Contraindications
- Hypersensitivity to decitabine
- Lactating women
Common side effects
- Myelosuppression
- Infections
- Febrile neutropenia
- Nausea
- Vomiting
Counselling Points
- Use effective contraception during treatment
- Avoid breastfeeding
- Monitor for signs of infection
Serious warnings
- Risk of severe infections
- Monitor for interstitial lung disease
On This Page
Loading package insert…
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
